Cargando…
Immune Checkpoint Inhibitor Induced Diabetes Mellitus Treated with Insulin and Metformin: Evolution of Diabetes Management in the Era of Immunotherapy
Immune checkpoint inhibitors (ICPIs) are a breakthrough therapy in oncology and have been approved by the Food and Drug Administration for the treatment of several malignancies. ICPIs have been reported to cause immune-mediated damage of islet cells leading to ICPI-induced type 1 diabetes mellitus (...
Autores principales: | Alrifai, Taha, Ali, Faisal Shaukat, Saleem, Sameer, Ruiz, Diana Carolina Miranda, Rifai, Dana, Younas, Sundas, Qureshi, Faisal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6875347/ https://www.ncbi.nlm.nih.gov/pubmed/31781446 http://dx.doi.org/10.1155/2019/8781347 |
Ejemplares similares
-
Metformin in Gestational Diabetes Mellitus
por: Reece, Sara Wilson, et al.
Publicado: (2014) -
Metformin in gestational diabetes mellitus
por: Tripathi, Reva, et al.
Publicado: (2017) -
Prevalence of type 2 diabetes, prediabetes, and gestational diabetes mellitus in women of childbearing age in Middle East and North Africa, 2000–2017: protocol for two systematic reviews and meta-analyses
por: Al-Rifai, Rami H., et al.
Publicado: (2018) -
Euglycemic Diabetic Ketoacidosis Accompanied by Severe Hypophosphatemia During Recovery in a Patient With Type 2 Diabetes Being Treated With Canagliflozin/Metformin Combination Therapy
por: Shoukat, Sonia, et al.
Publicado: (2017) -
Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus
por: Younas, Amna, et al.
Publicado: (2021)